Congenital Myasthenia (CM)
Also known as: Congenital Myasthenic Syndrome / Myasthenic Syndromes, Congenital / Congenital Myasthenic Syndromes / Congenital Myasthenia / Congenital myasthenic syndrome (disorder)
Drug | Drug Name | Drug Description |
---|---|---|
DB00545 | Pyridostigmine | A cholinesterase inhibitor used for symptomatic treatment of myasthenia gravis and congenital myasthenic syndromes and to reverse neuromuscular blockade by nondepolarizing muscle relaxants. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB00545 | Pyridostigmine | Acetylcholinesterase | target |
DB00545 | Pyridostigmine | Cholinesterase | target |
DB00545 | Pyridostigmine | Acetylcholinesterase | enzyme |
DB00545 | Pyridostigmine | Cholinesterase | enzyme |
DB00545 | Pyridostigmine | Cytochrome P450 3A4 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB01001 | Albuterol | 1 | Completed | 1 |
DB01364 | Ephedrine | 1 / 2 | Unknown Status | 1 |
DB11640 | Amifampridine | 3 | Completed | 1 |
DB11640 | Amifampridine | Not Available | Approved for Marketing | 1 |
DB11640 | Amifampridine | Not Available | No Longer Available | 4 |